Background
Ixabepilone(BMS-247550), an epothilone B analog, is an orally bioavailable microtubule inhibitor [1]. It could bind to tubulin and promote tubulin polymerization and microtubule stabilization, thereby arresting cells in the G2-M phase of the cell cycle and inducing tumor cell apoptosis[2].
In vitro: In a large panel of tumor cell lines, BMS-247550 was as active as epothilone B in inducing cytotoxicity. Of the 21 cells lines tested, the IC50 values were in the range of 1.4–34.5 nm. BMS-247550 almost completely blocked cells in mitosis as early as 8 h after the initiation of drug exposureat a concentration close to the IC90 (7.5 nm, clonogenic cytotoxicity assay) [2].
In vivo: BMS-247550 has clearly demonstrated antitumor activity that is superior to paclitaxel in both paclitaxel-sensitive and -resistant tumors. BMS-247550 was more efficacious than paclitaxel in all five paclitaxel-resistant tumors such as the clinically derived paclitaxel resistant Pat-7 ovarian carcinoma, the A2780Tax ovarian carcinoma that is resistant to paclitaxel because of tubulin mutations, the HCT116/VM46 MDR colon carcinoma, the clinically derived paclitaxel-resistant Pat-21 breast carcinoma, and the murine fibrosarcoma M5076. BMS-247550 produced antitumor activity equivalent to paclitaxel against three paclitaxel-sensitive human tumor xenografts such as A2780 human ovarian carcinoma, HCT116, and LS174T human colon carcinoma [2].
Clinical trials:Numerous phase I trials have evaluated the optimum dose and toxicity associated with ixabepilone. Various phase II studies were designed for patients with varying levels of previous therapies based on ample evidence of response and safety in early trials such as patients with taxane-refractory breast cancer, taxane-naive patients, both taxane-naive and taxane-refractory patients, taxane refractory patients[3].
参考文献:
[1].?Lee FY1, Borzilleri R,Fairchild CR, Kim SH, Long BH, Reventos-Suarez C, Vite GD, Rose WC, Kramer RA.BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy. Clin Cancer Res.2001 May;7(5):1429-37
[2].?Denduluri N, Low J A, Lee J J, et al. Phase II trial of ixabepilone, an epothilone B analog, in patients with metastatic breast cancer previously untreated with taxanes[J]. Journal of clinical oncology, 2007, 25(23): 3421-3427.
[3].?Shannon Puhalla, Adam Brufsky. Ixabepilone: a new chemotherapeutic option for refractory metastatic breast cancer. Biologics. 2008 Sep; 2(3): 505–515.
Protocol
Kinase experiment: | The potency with which BMS-247550 and paclitaxel polymerize tubulin isolated from calf brain is evaluated by Published techniques. Briefly, different concentrations of paclitaxel or BMS-247550 in polymerization buffer [0.1?M mes, 1 mM?EGTA, 0.5 mM?MgCl2 (pH 6.6)] are added to tubulin in polymerization buffer at 37°C in microcuvette wells of a Beckman. Model DU 7400 UV spectrophotometer. A final microtubule protein concentration of 1.0 mg/mL and compound concentrations of generally 2.5, 5.0, and 10 μM?are used. Initial slopes of absorbance (A280 nM) change, measured every 10 s, are calculated by the software program accompanying the instrument. |
Cell experiment: | HCT116 cells from cultures are collected by trypsinization after 1, 2, 4, 8, 16, and 24 h exposure to 7.5 nm of BMS-247550. Cells are pelleted and fixed in 80% ethanol at ?20°C. After an overnight storage at ?20°C, cells are rehydrated with PBS buffer and DNA stain by incubation with propidium iodide (5 μg/mL) in 0.1% RNase for 15-30 min. Fluorescence-activated cell sorter acquisition is performed using the FACS Calibur instrument and analysis is done using Cellquest and Modfit software. |
参考文献: [1]. John T. Hunt Discovery of Ixabepilone. Mol Cancer Ther February 2009 8; 275 |
没有评价数据